Teaching Inhaler Use With the INCA Device in a Community Pharmacy Setting
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02203266 |
Recruitment Status :
Completed
First Posted : July 29, 2014
Last Update Posted : July 18, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this trial is to discover whether providing feedback to patients from a device that records when and how well a patient uses a Seretide Diskus inhaler will lead to:
- Improved compliance with prescribed inhaler use
- Improved technique of inhaler use
- A reduction in respiratory health related outcomes caused by poor inhaler compliance and usage.
- An improvement in patient quality of life scores
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Asthma Pulmonary Disease, Chronic Obstructive | Device: Feedback Behavioral: Education | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 152 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | A Randomised, Parallel-group, Multi-centre Trial Using a Novel INCA Tracker Device to Measure and Monitor Compliance and Technique of Seretide Diskus Inhaler in a Community Pharmacy Setting |
Actual Study Start Date : | February 2014 |
Actual Primary Completion Date : | December 2016 |
Actual Study Completion Date : | January 2017 |
Arm | Intervention/treatment |
---|---|
Experimental: Feedback
Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
|
Device: Feedback
Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
Other Name: INCA Device |
Active Comparator: Demonstration
Current best practice - inhaler technique education
|
Behavioral: Education
Feedback on the patient's own inhaler technique as observed by pharmacist and education to support best use will be provided to patients in the demonstration group after 1,2 and 6 months. |
No Intervention: Control
Usual care in the community pharmacy setting
|
- Rate of adherence [ Time Frame: 2 months and 6 months ]The rate of adherence is the proportion of correctly taken drugs at the correct time relative to the prescribed interval.
- Rescue inhaled medication use [ Time Frame: Six months ]
- Rescue antibiotic and/or steroid medication use [ Time Frame: 6 months ]
- Quality of life [ Time Frame: 2 months and 6 months ]
- Adherence in the time domain [ Time Frame: Two months and six months ]
- Technique adherence [ Time Frame: Two months and six months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Must be 18 years old or above
- Capable of understanding and willing to provide voluntary informed consent before any protocol specific procedures are performed
- Capable of understanding and complying with the requirements of the protocol, and demonstrating a willingness to attend for all required visits.
- Able and willing to take inhaled medication.
- Have a valid prescription for use of a Seretide diskus inhaler or already using a Seretide diskus inhaler.
- Have a history of regular attendance in the pharmacy in which they are recruited which will be demonstrated by the subject having collected three prescriptions for any medication in that pharmacy in the six months preceeding their recruitment to the study.
Exclusion Criteria:
- Patient expressly reports that their physician has indicated that they will not be continuing to receive Seretide over the next 6 months

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02203266
Ireland | |
Boots Retail (Ireland) Limited | |
Dublin, Ireland |
Principal Investigator: | Richard Costello, Professor | Royal College of Surgeons in Ireland, Clinical Research Centre, Beaumont Hospital |
Responsible Party: | Professor Richard Costello, Beaumont Hospital |
ClinicalTrials.gov Identifier: | NCT02203266 |
Other Study ID Numbers: |
RC004 |
First Posted: | July 29, 2014 Key Record Dates |
Last Update Posted: | July 18, 2019 |
Last Verified: | July 2019 |
Medication Adherence Patient Compliance |
Pulmonary Disease, Chronic Obstructive Lung Diseases Respiratory Tract Diseases Lung Diseases, Obstructive |